Key statistics
On Thursday, Royalty Pharma PLC (RPRXN:MEX) closed at 775.06, 0.00% below its 52-week high of 775.06, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 775.06 |
|---|---|
| High | 775.06 |
| Low | 775.06 |
| Bid | 750.21 |
| Offer | 799.79 |
| Previous close | 775.06 |
| Average volume | 3.27k |
|---|---|
| Shares outstanding | 576.86m |
| Free float | 389.11m |
| P/E (TTM) | 25.38 |
| Market cap | 26.07bn USD |
| EPS (TTM) | 1.78 USD |
| Annual div (ADY) | 16.11 MXN |
|---|---|
| Annual div yield (ADY) | 2.08% |
| Div ex-date | Nov 14 2025 |
| Div pay-date | Dec 10 2025 |
Data delayed at least 20 minutes, as of Feb 12 2026 20:59 GMT.
More ▼
Announcements
- Royalty Pharma Reports Q4 and Full Year 2025 Results
- Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
- Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
- Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports Third Quarter 2025 Results
More ▼
